에 대한 최신 뉴스 IQVIA Hldgs (NYSE:IQV) 주식

IQVIA Hldgs

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings

Nvidia

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

Trading Ideas

General

ILMN

NVDA

엔비디아(NASDAQ:NVDA)의 제품은 GPU와 게임에 국한되지 않는다. 이 기술 회사는 현재 헬스케어 인공지능 분야에서도 주목받고 있다. 월요일에 열린 J.P. 모건의 헬스케어 컨퍼런스에서 애널리스트 할란 서(Harlan Sur)는 엔비디아의 전략적 위치와 향후 성장의 주요 동력을 강조했다. 이것이 월스트리트와 병원들이 주목하고 있는 이유이다.

엔비디아가 의료 AI로 10억 달러의 매출을 겨냥: 다음 성장의 지평으로 거듭날까?

stock chart-1863880_1920-60

News

BILL

ETSY

ICLR

MTCH

SDRL

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 여행 및 숙박에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.

엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소

IQVIA Holdings Inc

Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) will release earnings results for the first quarter, after the closing <a href="https://www.benzinga.com/quote/snap/earnings">bell on Tuesday, April 29</a>.
Analysts expect the Santa Monica, California-based company to report quarterly earnings at 4 cents per share, up from 3 cents per share in the year-ago period. Snap projects to report quarterly revenue at $1.35 billion, compared to $1.19 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 4, Snap reported quarterly earnings of 16 cents per share, which beat the analyst consensus estimate of 14 cents. Quarterly revenue came in at $1.55 billion, which beat the analyst consensus estimate of $1.54 billion and is an increase over revenue of $1.36 billion from the same period last year.
Snap shares rose 3.4% to close at $8.83 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Kelley maintained a Hold rating and cut the price target from $11 to $8 on April 23, 2025. This analyst has an accuracy rate of 83%.</li>
<li>Morgan Stanley analyst Brian Nowak maintained an Equal-Weight rating and slashed the price target from $10 to $8 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Canaccord Genuity analyst Maria Ripps maintained a Hold rating and slashed the price target from $13 to $10 on April 17, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Citigroup analyst Ronald Josey maintained a Neutral rating and cut the price target from $13.5 to $9 on April 14, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Goldman Sachs analyst Eric Sheridan maintained a Neutral rating and cut the price target from $13.5 to $9.5 on April 14, 2025. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying SNAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29033106/image-204-1024x584.png" alt="" class="wp-image-892210" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29033106/image-204-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29033106/image-204-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29033106/image-204-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29033106/image-204.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

SNAP

Snap Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt analyst Mike Genovese upgraded the rating for Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) from Sell to Neutral and raised the price target from $55 to $85. Arista Networks shares closed at $78.31 on Monday. <a href="https://www.benzinga.com/quote/anet/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Damian Karas upgraded the rating for Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) from Neutral to Buy and increased the price target from $157 to $190. Crane shares closed at $148.67 on Monday. <a href="https://www.benzinga.com/quote/CR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ANET stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29081343/image-214-1024x584.png" alt="" class="wp-image-892707" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29081343/image-214-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29081343/image-214-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29081343/image-214-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29081343/image-214.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ANET

VLRS

This Arista Networks Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Tuesday

Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) is in the spotlight ahead earnings Tuesday. Here&#8217;s what you <a href="https://www.benzinga.com//node/45046664">need to know.</a>
What To Know: Analysts&#8217; estimate first-quarter earnings of 3 cents per share and revenue of $1.35 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
The company previously guided for revenue between $1.23 billion and $1.36 billion and adjusted EBITDA between $40 million and $75 million for the first-quarter.
Snap also expects infrastructure costs per daily active user to be between 82 cents and 87 cents. Content, developer, advertising partner and other costs are expected to represent 19% to 20% of revenue.
In its last letter to shareholders, the company said, &#8220;As we look ahead to 2025, we see additional opportunities to invest productively in scaling our business given the foundational improvements we have made to our ad platform and the momentum we have established in our go to market initiatives, particularly the SMB segment. Our investment plans for 2025 reflect this optimism, alongside a strong commitment to make further financial progress towards profitability as we scale.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45067585/amazon-stock-tumbles-as-white-house-calls-tariff-visibility-plans-a-hostile-act">Amazon Stock Tumbles As White House Calls Tariff Visibility Plans A &#8216;Hostile&#8217; Act</a>
SNAP Price Action: At the time of writing, Snap stock is trading 1.0.8% higher at $8.92, per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image: via Shutterstock

Movers

What's Going On With Snap Stock Tuesday?

UBS analyst Timothy Arcuri maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Neutral and lowers the price target from $70 to $65.

SWKS

UBS Maintains Neutral on Skyworks Solutions, Lowers Price Target to $65

UBS analyst John Nadel maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Neutral and lowers the price target from $93 to $80.

UBS Maintains Neutral on Principal Financial Group, Lowers Price Target to $80

UBS analyst Pradeep Ramani maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $55 to $40.

UBS Maintains Neutral on ON Semiconductor, Lowers Price Target to $40

WIIM

Wells Fargo shares are trading higher after the company's board authorized a $40 billion stock repurchase program.

UBS analyst Kunal Madhukar maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $34 to $31.

UBS Maintains Neutral on Match Group, Lowers Price Target to $31

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $77 to $47. (Analyst Firm change from Stephens &amp; Co. to Guggenheim)

Downgrades

SWTX

Correction: Guggenheim Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47 (Firm change from Stephens & Co. to Guggenheim)

BMO Capital analyst Michael Zaremski maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Outperform and raises the price target from $92 to $96.

SIGI

BMO Capital Maintains Outperform on Selective Insurance Gr, Raises Price Target to $96

UBS analyst Taylor McGinnis maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Neutral and lowers the price target from $350 to $310.

MNDY

UBS Maintains Neutral on Monday.Com, Lowers Price Target to $310

BMO Capital analyst Ari Klein maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Perform and raises the price target from $230 to $240.

SBAC

BMO Capital Maintains Market Perform on SBA Communications, Raises Price Target to $240

UBS analyst Pradeep Ramani maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $70 to $55.

MCHP

UBS Maintains Buy on Microchip Technology, Lowers Price Target to $55

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 20 years by 8.88% on an annualized basis producing an average annual return of 16.92%. Currently, AZZ has a market capitalization of $2.57 billion. 
Buying $1000 In AZZ: If an investor had bought $1000 of AZZ stock 20 years ago, it would be worth $22,594.59 today based on a price of $86.00 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745937911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

BMO Capital analyst Andrew Strelzik maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and raises the price target from $515 to $540.

BMO Capital Maintains Outperform on Domino's Pizza, Raises Price Target to $540

UBS analyst Danielle Antalffy maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Neutral and lowers the price target from $19 to $16.25.

INMD

UBS Maintains Neutral on InMode, Lowers Price Target to $16.25

BMO Capital analyst James Thalacker maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Outperform and raises the price target from $77 to $79.

BMO Capital Maintains Outperform on CMS Energy, Raises Price Target to $79

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $37.

UBS Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $37

Piper Sandler analyst James Fish maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Neutral and raises the price target from $262 to $269.

FFIV

Piper Sandler Maintains Neutral on F5, Raises Price Target to $269

UBS analyst Timothy Arcuri maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral and lowers the price target from $115 to $90.

ENTG

UBS Maintains Neutral on Entegris, Lowers Price Target to $90

Press Releases

IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

IQVIA Releases 2024 Sustainability Report

IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025

IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

Medpace Hldgs

Mesa Laboratories

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

HSBC

Truist Securities

Barclays

Mizuho

Citigroup

엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 제품은 GPU와 게임에 국한되지 않는다. 이 기술 회사는 현재 <a href="https://www.benzinga.com/topic/artificial-intelligence">헬스케어 인공지능</a> 분야에서도 주목받고 있다.
월요일에 열린 J.P. 모건의 헬스케어 컨퍼런스에서 애널리스트 할란 서(Harlan Sur)는 엔비디아의 전략적 위치와 향후 성장의 주요 동력을 강조했다. 이것이 월스트리트와 병원들이 주목하고 있는 이유이다.
<h2 class="wp-block-heading">AI 에이전트가 구원투수로 나선다</h2>
최대 2,000만 명의 의료 인력 부족이 우려되는 상황에서, 엔비디아는 배달 로봇과 임상 대화를 위한 생성적 인공지능(AI)과 같은 AI 기반 솔루션으로 나섰다. 서는 노동력 부족으로 인한 이러한 에이전트 AI 솔루션에 대한 수요가 증가하고 있으며, 엔비디아가 이미 인트리보(Intrivo)와 어브릿지(Abridge)와 같은 회사와 협력하여 이러한 기술을 배포하고 있다고 언급했다.
이러한 &#8220;디지털 헬스 에이전트&#8221;는 단순한 미래형 장난감이 아니라, 중요한 인력 격차를 채우는 데 필수적인 역할을 하고 있다. 인트리보와 어브릿지와 같은 파트너십은 엔비디아가 얻고 있는 실제적인 추진력을 강조한다.
또한 읽어보기: <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">젠슨 황, 양자 컴퓨팅은 20년 후라고 했지만, 엔비디아는 전략적 채용에 대규모 투자</a>
<h2 class="wp-block-heading">엔비디아: 대형 플랫폼, 더 큰 야망</h2>
엔비디아의 강력한 데이터 센터 플랫폼인 옴니버스(Omniverse), 코스모스(Cosmos) 및 DGX 클라우드는 헬스케어 AI 채택을 새로운 차원으로 끌어올리고 있다. 서에 따르면, 온프레미스, 클라우드 기반 또는 하이브리드 모델 전반에 걸친 유연성은 기업 채택을 촉진하는 데 도움이 된다.
2026 회계연도까지 연간 10억 달러의 반복적인 헬스케어 매출이 예상되는 가운데, 이 회사는 수천억 달러 규모의 시장을 겨냥하고 있다.
<h2 class="wp-block-heading">엔비디아의 기술이 의학과 만나다</h2>
약물 발견에서 로봇 보조 수술에 이르기까지, 엔비디아는 AI를 의료 기기와 병원 운영 전반에 통합한다. 서는 엔비디아가 로봇 훈련과 의료 기술 개발을 위한 물리적 환경을 만들기 위해 옴니버스와 코스모스 플랫폼을 사용하고 있다고 강조했다.
<h2 class="wp-block-heading">유전체학, 파트너십, 경쟁력</h2>
아이큐비아 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 및 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)와의 새로운 협력은 엔비디아의 헬스케어 AI 지배를 향한 공격적인 추진을 나타낸다. 서는 이러한 전략적 파트너십이 엔비디아의 헬스케어 AI 로드맵에서 중요한 단계라고 언급했다.
약물 발견에서 유전체 연구에 이르기까지, 엔비디아는 인류 건강을 재편할 수 있는 혁신을 열어주기 위해 노력하고 있다.
서의 전망이 맞다면, 헬스케어 AI는 엔비디아의 다음 10억 달러 규모의 기회가 될 수 있다.
다음으로 읽어보세요: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A1%B0-%EB%B0%94%EC%9D%B4%EB%93%A0-vs-%EC%A0%A0%EC%8A%A8-%ED%99%A9-%EC%83%88%EB%A1%9C%EC%9A%B4-%EC%B9%A9-%EC%88%98%EC%B6%9C-%EA%B7%9C%EC%A0%9C%EA%B0%80-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84/" target="_blank" rel="noopener">조 바이든 vs 젠슨 황: 백악관의 새로운 칩 수출 규제가 엔비디아에 미치는 의미</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">여행 및 숙박</a>에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.
여기 3분기에 엘리엇이 새로 취득한 모든 포지션이 있다:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) 콜 옵션</li>
</ul>
<ul>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) 콜 옵션</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 콜 옵션</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) 콜 옵션</li>
</ul>
<ul>
<li>알래스카 에어 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) 콜 옵션</li>
</ul>
<ul>
<li>아메리칸 항공 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이콘 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이큐비아 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 콜 옵션</li>
</ul>
<ul>
<li>메리어트 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) 풋 옵션</li>
</ul>
<ul>
<li>힐튼 월드와이드 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) 풋 옵션</li>
</ul>
<ul>
<li>에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) 풋 옵션</li>
</ul>
<ul>
<li>하얏트 호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) 풋 옵션</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) 풋 옵션</li>
</ul>
3분기 동안 엘리엇이 늘린 모든 포지션을 살펴보겠다:
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 919% 증가</li>
</ul>
<ul>
<li>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) 90% 증가</li>
</ul>
<ul>
<li>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) 11% 증가</li>
</ul>
<ul>
<li>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) 3% 증가</li>
</ul>
이번 분기에 엘리엇이 줄인 모든 포지션은 다음과 같다:
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) 24% 감소</li>
</ul>
<ul>
<li>블랙라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) 20% 감소</li>
</ul>
<ul>
<li>씨드릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) 9% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 7% 감소</li>
</ul>
위의 정보는 분기 동안 증가하거나 줄어들거나 완전히 매도된 콜 또는 풋 옵션을 포함하지 않았다.
이 정보는 <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>의 비교 도구를 사용하여 수집되었습니다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">넬슨 펠츠의 트라이언 펀드 매니지먼트가 대선 전 포트폴리오를 재편성</a></li>
</ul>
사진: Pixabay.

Comments

IQVIA Hldgs

뉴스

에 대한 최신 뉴스 IQVIA Hldgs (NYSE:IQV) 주식

화요일, 1월 14, 2025

금요일, 11월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌